Cargando…

Mucositis and Infection in Hematology Patients

Survival in patients with hematological malignancies has improved over the years, both due to major developments in anticancer treatment, as well as in supportive care. Nevertheless, important and debilitating complications of intensive treatment regimens still frequently occur, including mucositis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Blijlevens, Nicole M. A., de Mooij, Charlotte E. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253974/
https://www.ncbi.nlm.nih.gov/pubmed/37298545
http://dx.doi.org/10.3390/ijms24119592
_version_ 1785056533743140864
author Blijlevens, Nicole M. A.
de Mooij, Charlotte E. M.
author_facet Blijlevens, Nicole M. A.
de Mooij, Charlotte E. M.
author_sort Blijlevens, Nicole M. A.
collection PubMed
description Survival in patients with hematological malignancies has improved over the years, both due to major developments in anticancer treatment, as well as in supportive care. Nevertheless, important and debilitating complications of intensive treatment regimens still frequently occur, including mucositis, fever and bloodstream infections. Exploring potential interacting mechanisms and directed therapies to counteract mucosal barrier injury is of the utmost importance if we are to continue to improve care for this increasingly growing patient population. In this perspective, I highlight recent advances in our understanding of the relation of mucositis and infection.
format Online
Article
Text
id pubmed-10253974
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102539742023-06-10 Mucositis and Infection in Hematology Patients Blijlevens, Nicole M. A. de Mooij, Charlotte E. M. Int J Mol Sci Perspective Survival in patients with hematological malignancies has improved over the years, both due to major developments in anticancer treatment, as well as in supportive care. Nevertheless, important and debilitating complications of intensive treatment regimens still frequently occur, including mucositis, fever and bloodstream infections. Exploring potential interacting mechanisms and directed therapies to counteract mucosal barrier injury is of the utmost importance if we are to continue to improve care for this increasingly growing patient population. In this perspective, I highlight recent advances in our understanding of the relation of mucositis and infection. MDPI 2023-05-31 /pmc/articles/PMC10253974/ /pubmed/37298545 http://dx.doi.org/10.3390/ijms24119592 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Blijlevens, Nicole M. A.
de Mooij, Charlotte E. M.
Mucositis and Infection in Hematology Patients
title Mucositis and Infection in Hematology Patients
title_full Mucositis and Infection in Hematology Patients
title_fullStr Mucositis and Infection in Hematology Patients
title_full_unstemmed Mucositis and Infection in Hematology Patients
title_short Mucositis and Infection in Hematology Patients
title_sort mucositis and infection in hematology patients
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253974/
https://www.ncbi.nlm.nih.gov/pubmed/37298545
http://dx.doi.org/10.3390/ijms24119592
work_keys_str_mv AT blijlevensnicolema mucositisandinfectioninhematologypatients
AT demooijcharlotteem mucositisandinfectioninhematologypatients